Kiniksa(KNSA) - 2024 Q1 - Quarterly Results

Exhibit 99.1 – ARCALYST 2024 expected net product revenue increased to $370 -$390 million – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, BERMUDA – April 23, 2024 – Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution. "One of the drive ...